Trial reportThorax1994
Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group.
Trial report in Thorax, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2023Pooled it
- Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital.The Cochrane database of systematic reviews · 2014Pooled it
- Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.The Cochrane database of systematic reviews · 2014Pooled it
- Inhaled corticosteroids for stable chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2012Pooled it
- Inhaled beclomethasone versus placebo for chronic asthma.The Cochrane database of systematic reviews · 2005Pooled it
- Anticholinergic agents for chronic asthma in adults.The Cochrane database of systematic reviews · 2004Pooled it
- Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1999Guideline
- Testing bronchial hyper-responsiveness: provocation or peak expiratory flow variability?The British journal of general practice : the journal of the Royal College of General Practitioners · 1997Trial
- Predicting clinical exacerbations using respiratory oscillometry during home telemonitoring of patients taking medium-/high-dose asthma treatment.ERJ open research · 2026Article
- A Pilot Randomized Trial of As-Needed Budesonide-Formoterol for Stepping Down Controller Treatment in Moderate Asthma with Complete Remission.Tuberculosis and respiratory diseases · 2022Article
- IL-1β augments TGF-β inducing epithelial-mesenchymal transition of epithelial cells and associates with poor pulmonary function improvement in neutrophilic asthmatics.Respiratory research · 2021Article
- Predicting Treatment Outcomes Using Explainable Machine Learning in Children with Asthma.Children (Basel, Switzerland) · 2021Article
- Post hoc analysis of initial treatments and control status in the INITIAL study: an observational study of newly diagnosed patients with asthma.BMC pulmonary medicine · 2020Observational
- Novel approach to continuous adventitious respiratory sound analysis for the assessment of bronchodilator response.PloS one · 2017Article
- Systems Biology and Clinical Practice in Respiratory Medicine. The Twain Shall Meet.American journal of respiratory and critical care medicine · 2016Article
- The Danish National Database for Asthma: establishing clinical quality indicators.European clinical respiratory journal · 2016Review
- Pulmonary function testing and complications of laparoscopic bariatric surgery.Obesity surgery · 2013Article
- Endpoints in respiratory diseases.European journal of clinical pharmacology · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite effective treatments, the morbidity and mortality of obstructive airways disease (asthma and COPD) remains high. Home monitoring of peak expiratory flow (PEF) is increasingly being advocated as an aid to better management of obstructive airways disease. The few available studies describing effects of treatment on the level and variation of PEF have involved relatively small numbers of subjects and did not use control groups.
methodsPatients aged 18-60 years were selected with PC20 < or = 8 mg/ml and FEV1 < 95% confidence interval of predicted normal. They were randomised to receive, in addition to a beta 2 agonist, either an inhaled corticosteroid (BA+CS), an anticholinergic (BA+AC), or a placebo (BA+PL). One hundred and forty one of these subjects with moderately severe obstructive airways disease completed seven periods of two weeks of morning and afternoon PEF measurements at home during 18 months of blind follow up.
resultsImprovements in PEF occurred within the first three months of treatment with BA+CS and was subsequently maintained: the mean (SE) increase in morning PEF was 51 (8) l/min in the BA+CS group compared with no change in the other two groups. Similarly, afternoon PEF increased by 22 (7) l/min. Diurnal variation in PEF (amplitude %mean) decreased from 18.0% to 10.2% in the first three months of treatment with BA+CS. Within-subject relations between changes in diurnal variation in PEF and changes in PC20 were found to be predominantly negative (median rho-0.40) but with a large scatter. Relations between diurnal variation in PEF and changes in symptom scores, FEV1, and bronchodilator response were even weaker.
conclusionsIn patients with moderately severe obstructive airways disease, PEF rates and variation are greatly improved by inhaled corticosteroids. Since the relation of diurnal PEF variation with PC20, symptoms, FEV1, and bronchodilator response were all weak, these markers of disease severity may all provide different information on the actual disease state. PEF measurements should be used in addition to the other markers but not instead of them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.